Marijuana (THC/CBD) Gummies and Liver Function
Marijuana products that contain cannabidiol (CBD) can cause liver enzyme elevations. [1]
Clinically apparent liver injury with jaundice has not been convincingly linked to prescription CBD, but cases of enzyme elevations occur with sufficiently high exposure. [1]
What the Evidence Shows
- CBD has been associated with frequent serum transaminase (ALT/AST) elevations during therapy in clinical experience. [1]
- Published liver safety data in healthy adults show clinically meaningful rates of ALT elevations during CBD exposure. [2]
- Case reports of acute hepatitis temporally associated with marijuana use have been described, but causality in individual cases can be difficult to prove. [3]
CBD-Related Liver Enzyme Elevations
- In a phase I clinical trial in healthy adults receiving CBD, peak ALT values exceeded the upper limit of normal in 44% of participants. [2]
- In the same study, ALT/AST values met drug-induced liver injury criteria in 31% of participants. [2]
- LiverTox reports that high doses of CBD are associated with frequent liver enzyme elevations and that clinically apparent injury with jaundice has not been clearly established in prescription CBD populations. [1]
THC-Containing Gummies (Marijuana) and Liver Injury
- LiverTox notes that liver injury attributable to marijuana/cannabinoids is not well characterized and that available evidence does not establish a consistent, common pattern comparable to well-defined hepatotoxins. [4]
- Marijuana-induced acute hepatitis has been reported in at least one published case report. [3]
Product and Dose Factors
- Higher CBD exposure is associated with greater likelihood of transaminase elevations in available trial data. [2]
- Variable potency and contaminants in non-regulated products can create additional risk for liver test abnormalities, including from ingredients other than CBD/THC. [5]
Drug Interactions That Increase Risk of Hepatotoxicity
- CBD can affect drug metabolism pathways, which can increase exposure to other medications that may contribute to liver injury. [6]
Monitoring and When to Seek Medical Evaluation
- Clinically significant symptoms such as jaundice, dark urine, right upper quadrant pain, or marked fatigue during cannabinoid use warrant prompt evaluation for drug-induced liver injury. [1]
- LiverTox emphasizes monitoring and clinical assessment for liver injury when using agents associated with transaminase elevations. [1]
Practical Clinical Guidance for Gummies Use
- Avoiding unnecessary CBD/THC gummy exposure is recommended when liver disease is present or when other hepatotoxic medications are used. [1]
- If CBD products are used, baseline liver function tests and follow-up testing are commonly considered in settings where clinically meaningful transaminase elevations are plausible based on dose and risk factors. [1]
- Discontinuation or dose reduction is recommended when significant hepatotoxicity is identified or suspected during CBD therapy. [6]
Common Patterns Observed
- The most consistently observed effect across evidence is transaminase elevation rather than proven severe jaundiced hepatitis. [1]
- Some individuals experience enzyme elevations meeting drug-induced liver injury criteria during CBD exposure. [2]